Skip to main content
AGTCinactive

APPLIED GENETIC TECHNOLOGIES CORP

Biopharma developer (SEC filing verified)·Commercial·CEO: Susan B. Washer
Ophthalmology

AGTC evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for AGTC—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

4.9/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

—

Cash Runway

6.6 mo

Lead Asset

achma3 (Phase 1/Phase 2)

Next Catalyst

—

Financial data as of Sep 30, 2022.

Tracking 3 pipeline candidates for APPLIED GENETIC TECHNOLOGIES CORP.

Run APPLIED GENETIC TECHNOLOGIES CORP through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available APPLIED GENETIC TECHNOLOGIES CORP facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway1.8

6.6 months

Financial Health3.3

D/E 2.25

Pipeline Maturity8.5

Lead: Phase 2/Phase 3

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Run my thesis on this company

Pipeline

Run my thesis on this company

Financials

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is APPLIED GENETIC TECHNOLOGIES CORP's lead drug candidate?

APPLIED GENETIC TECHNOLOGIES CORP's most advanced tracked candidate is achma3 (Phase 1/Phase 2) for Achromatopsia (ACHM) caused by mutations in the CNGA3 gene.

Who is the CEO of APPLIED GENETIC TECHNOLOGIES CORP?

Susan B. Washer is the chief executive officer of APPLIED GENETIC TECHNOLOGIES CORP (AGTC).

What therapeutic areas does APPLIED GENETIC TECHNOLOGIES CORP focus on?

APPLIED GENETIC TECHNOLOGIES CORP develops therapies across Ophthalmology.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.